Clinical Trials Directory

Trials / Completed

CompletedNCT01423305

Phase I Pharmacokinetic Study (BF-BLOCK)

Effect of Charcoal on Gastrointestinal Absorption of Budesonide and Formoterol

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
20 (actual)
Sponsor
Orion Corporation, Orion Pharma · Industry
Sex
All
Age
18 Years – 60 Years
Healthy volunteers
Accepted

Summary

The objective of the study is to assess if charcoal prevents the absorption of budesonide and formoterol via GI track. The assessment will be based on comparing the pharmacokinetic parameter area under the concentration-time curve.

Conditions

Interventions

TypeNameDescription
DRUGBudesonide/formoterol capsule.Oral administration with concomitant charcoal.
DRUGBudesonide/formoterol capsule for oral adm.Oral administration without concomitant charcoal.

Timeline

Start date
2011-08-01
Primary completion
2011-10-01
Completion
2011-10-01
First posted
2011-08-25
Last updated
2011-10-21

Locations

1 site across 1 country: Finland

Source: ClinicalTrials.gov record NCT01423305. Inclusion in this directory is not an endorsement.

Phase I Pharmacokinetic Study (BF-BLOCK) (NCT01423305) · Clinical Trials Directory